Home
Conditions
Flaviviridae Infections

Clinical trial condition

Flaviviridae Infections

Explore clinical trials studying Flaviviridae Infections. Study availability and eligibility vary by location and protocol.

2,144 public trials 77 recruiting studies

Refine in advanced search Browse all conditions

Flaviviridae Infections trial results

Completed

A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients

NCT00801255

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Adelaide, Australia

Heidelberg, Australia

Melbourne, Australia

Christchurch, New Zealand

View Trial Details

Completed

An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1

NCT01750216

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Bydgoszcz, Poland

Bytom, Poland

Chorzów, Poland

Ciechanów, Poland

View all 14 locations

View Trial Details

Completed

An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)

NCT01344889

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Elbasan, Albania

Tirana, Albania

Algiers, Algeria

Bahrain

View all 260 locations

View Trial Details

Completed

A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis

NCT01749150

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Busan, South Korea

Seoul, South Korea

Seoul, South Korea

Seoul, South Korea

View all 13 locations

View Trial Details

Completed

A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

NCT01057667

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: La Jolla, California, United States

Bradenton, Florida, United States

Atlanta, Georgia, United States

Honolulu, Hawaii, United States

View all 25 locations

View Trial Details

Completed

An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection

NCT01671046

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Rio de Janeiro, Brazil

Rio de Janeiro, Brazil

Botucatu, São Paulo, Brazil

Campinas, São Paulo, Brazil

View Trial Details

Completed

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection

NCT01220947

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: La Jolla, California, United States

Sacramento, California, United States

San Diego, California, United States

San Francisco, California, United States

View all 68 locations

View Trial Details

Completed

A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1

NCT01185860

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Montpellier, France

Christchurch, New Zealand

Grafton, New Zealand

Warsaw, Poland

View Trial Details

Completed

A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C

NCT01591460

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Graz, Austria

Innsbruck, Austria

Linz, Austria

Vienna, Austria

View all 32 locations

View Trial Details

Completed

A Study on Safety, Tolerability and Pharmacokinetics of RO5303253 in Healthy Volunteers and Patients With Chronic Hepatitis C Genotype 1

NCT01181024

Conditions: Blood-Borne Infections, Bronchial Diseases, Bronchiolitis, +20 more
Locations: Grafton, New Zealand

View Trial Details

Flaviviridae Infections

Flaviviridae Infections trial results

Related conditions